Takeda’s $600M Insilico Deal Ties AI Discovery to Clinical Milestones
Insilico will identify targets and design molecules while Takeda assumes development responsibility and pays as candidates cross scientific and commercial gates.
Share
Get the AI developments that matter, delivered to your inbox.
Posts by tag
Input your search keywords and press Enter.